Skip to Content
Merck
CN
  • SET8 is a novel negative regulator of TGF-β signaling in a methylation-independent manner.

SET8 is a novel negative regulator of TGF-β signaling in a methylation-independent manner.

Scientific reports (2023-12-22)
Mai Nagasaka, Yasumichi Inoue, Yuji Nagao, Chiharu Miyajima, Daisuke Morishita, Hiromasa Aoki, Mineyoshi Aoyama, Takeshi Imamura, Hidetoshi Hayashi
ABSTRACT

Transforming growth factor β (TGF-β) is a multifunctional cytokine that induces a diverse set of cellular processes principally through Smad-dependent transcription. Transcriptional responses induced by Smads are tightly regulated by Smad cofactors and histone modifications; however, the underlying mechanisms have not yet been elucidated in detail. We herein report lysine methyltransferase SET8 as a negative regulator of TGF-β signaling. SET8 physically associates with Smad2/3 and negatively affects transcriptional activation by TGF-β in a catalytic activity-independent manner. The depletion of SET8 results in an increase in TGF-β-induced plasminogen activator inhibitor-1 (PAI-1) and p21 expression and enhances the antiproliferative effects of TGF-β. Mechanistically, SET8 occupies the PAI-1 and p21 promoters, and a treatment with TGF-β triggers the replacement of the suppressive binding of SET8 with p300 on these promoters, possibly to promote gene transcription. Collectively, the present results reveal a novel role for SET8 in the negative regulation of TGF-β signaling.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-SETD8 (hPR-SET7) Antibody, from rabbit, purified by affinity chromatography